Abstract:To the editor —We read with great interest the recent article by Falcone et al [1] on the clinical features and outcomes of infections caused by metallo-β-lactamase (MBL)–producing Enterobacterales. In their prospective observational study, 343 patients were included, and the 30-day mortality was 29.7%. In a previous prospective, observational study of patients with MBL bloodstream infections, it was shown that the combination of ceftazidime-avibactam (CZA) plus aztreonam (ATM) was associated with reduced mortality risk compared with colistin-containing regimens [2]. The combination of CZA + ATM is recommended in current guidelines as the first-line option against infections by MBL-producing Enterobacterales [3–5]. It is noteworthy in the commented study that although the combination of CZA + ATM did lead to lower mortality (22.3%) compared with colistin-containing regimens (50%) or cefiderocol-containing regimens (33%), it was not the best treatment option in terms of patient survival. Specifically, patients who received "other active antibiotics" (OAAs) presented a 30-day mortality rate of 13.5% (5 of 37). However, the Kaplan–Meier survival curve of the OAA group is reversely presented with the CZA + ATM curve, leading to some confusion (Figure 3). In addition, there is a discrepancy in mortality rates for the OAA group; as noted in the Results section, mortality was 13.5% (5 of 37), while in Figure 2, the number presented above the corresponding bar was even lower (3 of 37, 8.1%; P = .046 versus CZA + ATM, χ 2 test). A more detailed look at the regimens used in the OAA group (Table 3) reveals that most patients received a fosfomycin-containing regimen; interestingly, 15 of 37 had received fosfomycin monotherapy, 2 of 37 received a combination with meropenem or gentamycin, respectively, while 16 patients received tigecycline ± fosfomycin, without any further clarification. Although the mortality by individual regimen is not provided in the article, the worst mortality scenario for the fosfomycin-containing regimen could be calculated if we attribute all 5 deaths in the OAA group to the fosfomycin-containing regimen and consider the minimum number of patients who could have been included in this group, which is 18 (counting that at least 1 patient in the tigecycline ± fosfomycin group received fosfomycin in addition to tigecycline). In this case, the worst mortality rate for the fosfomycin-containing regimen would be 5 of 18 (27.7%), which is the second-best treatment outcome. However, given the fact that 17.5% of the enrolled patients had complicated urinary tract infections, for which tigecycline is not an option, while 75.5% of cases suffered from bloodstream infections and hospital-acquired or ventilator-associated pneumonia, for which tigecycline should not be used as monotherapy, it is tempting to speculate that a significant portion of the tigecycline ± fosfomycin subgroup may have received combination therapy with fosfomycin. This would be interpreted as an even lower mortality rate for the fosfomycin-based regimen in the OAA group; nevertheless, these important data are lacking. In addition, the in vitro susceptibility rate of MBL-producing Enterobacterales to fosfomycin is quite sufficient (67.1%), according to Table 1. However, we are cautious in interpreting these data since susceptibility and resistance rates for several antibiotics are presented in reverse order. Taking into consideration that this is the largest clinical study on MBL-producing Enterobacterales infections published to date, it would be very helpful if the authors could further clarify the promising results of the OAA group, with a special emphasis on the role of fosfomycin and the type of infection.

Clinical Features and Outcomes of Infections Caused by Metallo-β-Lactamase-Producing Enterobacterales: A 3-Year Prospective Study From an Endemic Area

[Patients of Escherichia Coli Bloodstream Infection: Analysis of Antibiotic Resistance and Predictors of Mortality].

Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing Enterobacterales During a Regional Outbreak

Carbapenem resistance in Enterobacterales: Predicting clinical outcomes in bloodstream infections

Risk Factors for 30-Day Mortality in Nosocomial Enterococcal Bloodstream Infections

Bloodstream infections due to multi-drug resistant bacteria in the emergency department: prevalence, risk factors and outcomes—a retrospective observational study

Mortality and Risk Factors of Death in Patients with AmpC β-Lactamase Producing Enterobacterales Bloodstream Infection: A Cohort Study

Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network)

The Role of Fosfomycin-Containing Regimens in Reducing Mortality From Infections Caused by Metallo-β-Lactamase–Producing Enterobacterales

Risk Factors and Outcomes in Non-Transplant Patients with Extended-Spectrum Beta-Lactamase-producing Escherichia Coli Bacteremia: a Retrospective Study from 2013 to 2016

Association between multidrug-resistant bacteria and outcomes in intensive care unit patients: a non-interventional study

A Retrospective Analysis of Risk Factors and Outcomes in Patients with Extended-Spectrum Beta-Lactamase-producing Escherichia Coli Bloodstream Infections.

Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant <i>Enterobacterales</i>

Bloodstream Infections Due to Carbapenem-Resistant Enterobacteriaceae in Hematological Patients: Assessment of Risk Factors for Mortality and Treatment Options

Association of piperacillin/tazobactam MIC and mortality in a cohort of ceftriaxone-resistant Escherichia coli bloodstream infections treated with piperacillin/tazobactam and carbapenems: a multicentric propensity score-weighted observational cohort study

Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study.

The Challenge of Treating Infections Caused by Metallo‐β‐Lactamase–Producing Gram-Negative Bacteria: A Narrative Review

Epidemiology and outcome of anaerobic bacteremia in a tertiary hospital

Epidemiology and Clinical Outcomes of Multidrug-resistant, Gram-negative Bloodstream Infections in a European Tertiary Pediatric Hospital During a 12-month Period

Clinical characteristics of bloodstream infections caused by Enterococci and prognostic factors

Nosocomial Gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes